Evaluation of potential predictors for RBC-TI.
| Response no | Response yes | ||
|---|---|---|---|
| Male | 5 | 2 | 0.020 |
| Female | 4 | 17 | |
| Age | 7 | 8 | 0.086 |
| Age≥median | 2 | 11 | |
| MDS diagnosis to lenalidomide initiation<2 yr | 4 | 11 | 0.410 |
| MDS diagnosis to lenalidomide initiation≥2 yr | 5 | 8 | |
| IPSS low | 5 | 10 | 0.604 |
| IPSS intermediate-1 | 4 | 9 | |
| Pre-treatment red blood cell transfusion≤4 U/8 wk | 3 | 11 | 0.210 |
| Pre-treatment red blood cell transfusion>4U/8 wk | 6 | 8 | |
| Pre-treatment neutrophil≥1,000/mL | 5 | 16 | 0.123 |
| Pre-treatment neutrophil<1,000/mL | 4 | 3 | |
| Pre-treatment platelet≥150K/mL | 5 | 17 | 0.064 |
| Pre-treatment platelet<150K/mL | 4 | 2 | |
| Development of thrombocytopenia during treatment | 1 | 7 | 0.038 |
| No development of thrombocytopenia during treatment | 8 | 12 |
Abbreviation: IPSS, International prognostic scoring system.
Blood Res 2021;56:102~108 https://doi.org/10.5045/br.2021.2021086
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd